These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
356 related articles for article (PubMed ID: 31842958)
21. Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. Misale S; Arena S; Lamba S; Siravegna G; Lallo A; Hobor S; Russo M; Buscarino M; Lazzari L; Sartore-Bianchi A; Bencardino K; Amatu A; Lauricella C; Valtorta E; Siena S; Di Nicolantonio F; Bardelli A Sci Transl Med; 2014 Feb; 6(224):224ra26. PubMed ID: 24553387 [TBL] [Abstract][Full Text] [Related]
22. Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC. Della Corte CM; Ciaramella V; Ramkumar K; Vicidomini G; Fiorelli A; Nardone V; Cappabianca S; Cozzolino I; Zito Marino F; Di Guida G; Wang Q; Cardnell R; Gay CM; Ciardiello D; Martinelli E; Troiani T; Martini G; Napolitano S; Wang J; Byers LA; Ciardiello F; Morgillo F J Transl Med; 2022 Nov; 20(1):541. PubMed ID: 36419183 [TBL] [Abstract][Full Text] [Related]
23. HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF-Mutant Colorectal Cancer by Downregulation of c-FLIPL. Carson R; Celtikci B; Fenning C; Javadi A; Crawford N; Carbonell LP; Lawler M; Longley DB; Johnston PG; Van Schaeybroeck S Clin Cancer Res; 2015 Jul; 21(14):3230-3240. PubMed ID: 25813020 [TBL] [Abstract][Full Text] [Related]
24. MEK Inhibition Remodels the Immune Landscape of Mutant Yang B; Li X; Fu Y; Guo E; Ye Y; Li F; Liu S; Xiao R; Liu C; Lu F; Huang J; Qin T; Han L; Peng G; Mills GB; Sun C; Chen G Cancer Res; 2021 May; 81(10):2714-2729. PubMed ID: 33589518 [TBL] [Abstract][Full Text] [Related]
25. CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma. Zhou J; Wu Z; Wong G; Pectasides E; Nagaraja A; Stachler M; Zhang H; Chen T; Zhang H; Liu JB; Xu X; Sicinska E; Sanchez-Vega F; Rustgi AK; Diehl JA; Wong KK; Bass AJ Nat Commun; 2017 Jan; 8():13897. PubMed ID: 28059068 [TBL] [Abstract][Full Text] [Related]
26. Targeting MEK/COX-2 axis improve immunotherapy efficacy in dMMR colorectal cancer with PIK3CA overexpression. Peng K; Liu Y; Liu S; Wang Z; Zhang H; He W; Jin Y; Wang L; Xia X; Xia L Cell Oncol (Dordr); 2024 Jun; 47(3):1043-1058. PubMed ID: 38315285 [TBL] [Abstract][Full Text] [Related]
28. RAS-Mitogen-Activated Protein Kinase Signal Is Required for Enhanced PD-L1 Expression in Human Lung Cancers. Sumimoto H; Takano A; Teramoto K; Daigo Y PLoS One; 2016; 11(11):e0166626. PubMed ID: 27846317 [TBL] [Abstract][Full Text] [Related]
29. Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. Napolitano S; Martini G; Rinaldi B; Martinelli E; Donniacuo M; Berrino L; Vitagliano D; Morgillo F; Barra G; De Palma R; Merolla F; Ciardiello F; Troiani T Clin Cancer Res; 2015 Jul; 21(13):2975-83. PubMed ID: 25838391 [TBL] [Abstract][Full Text] [Related]
33. Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers. Hata AN; Rowley S; Archibald HL; Gomez-Caraballo M; Siddiqui FM; Ji F; Jung J; Light M; Lee JS; Debussche L; Sidhu S; Sadreyev RI; Watters J; Engelman JA Oncogene; 2017 Nov; 36(47):6581-6591. PubMed ID: 28783173 [TBL] [Abstract][Full Text] [Related]
34. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells. Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727 [TBL] [Abstract][Full Text] [Related]
35. AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer. Ye H; Liu Y; Wu K; Luo H; Cui L Cell Commun Signal; 2020 Jul; 18(1):115. PubMed ID: 32703218 [TBL] [Abstract][Full Text] [Related]
36. Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models. Del Curatolo A; Conciatori F; Cesta Incani U; Bazzichetto C; Falcone I; Corbo V; D'Agosto S; Eramo A; Sette G; Sperduti I; De Luca T; Marabese M; Shirasawa S; De Maria R; Scarpa A; Broggini M; Del Bufalo D; Cognetti F; Milella M; Ciuffreda L J Exp Clin Cancer Res; 2018 Jul; 37(1):140. PubMed ID: 29986755 [TBL] [Abstract][Full Text] [Related]
37. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer. Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141 [TBL] [Abstract][Full Text] [Related]
38. The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment. Poon E; Mullins S; Watkins A; Williams GS; Koopmann JO; Di Genova G; Cumberbatch M; Veldman-Jones M; Grosskurth SE; Sah V; Schuller A; Reimer C; Dovedi SJ; Smith PD; Stewart R; Wilkinson RW J Immunother Cancer; 2017 Aug; 5(1):63. PubMed ID: 28807001 [TBL] [Abstract][Full Text] [Related]
39. Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody. Stewart R; Morrow M; Hammond SA; Mulgrew K; Marcus D; Poon E; Watkins A; Mullins S; Chodorge M; Andrews J; Bannister D; Dick E; Crawford N; Parmentier J; Alimzhanov M; Babcook JS; Foltz IN; Buchanan A; Bedian V; Wilkinson RW; McCourt M Cancer Immunol Res; 2015 Sep; 3(9):1052-62. PubMed ID: 25943534 [TBL] [Abstract][Full Text] [Related]
40. Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer. Kitai H; Ebi H; Tomida S; Floros KV; Kotani H; Adachi Y; Oizumi S; Nishimura M; Faber AC; Yano S Cancer Discov; 2016 Jul; 6(7):754-69. PubMed ID: 27154822 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]